ArticlemAbs2026
Multidimensional maturation of antibody variable domains with machine-learning assistance.
Article in mAbs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
In antibody development, a mutagenesis approach has been widely used to improve affinity, but such mutations often compromise biophysical properties. Here, we combined molecular evolution with machine learning to simultaneously improve affinity and expression level of camelid heavy-chain antibody variable domains (VHHs). Using phage display and deep sequencing, we selected five residues in an anti-SARS-CoV-2 VHH for affinity maturation. We constructed training data using experimentally measured expression levels and target affinities of 117 variants with randomized residues. Machine-learning-predicted top-rank variants showed improved expression level and affinity compared to variants in the training data. Several variants achieved 50-70-fold stronger affinities in the pico-molar range and 4-5-fold higher expression level than wild-type. Furthermore, one variant showed 9.5°C improvement in thermal stability. These results highlight the utility of machine learning-assisted molecular evolution as a strategy for multidimensional optimization of antibody properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.